Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-08 pm EDT 		5-day change 1st Jan Change
4.82 USD -9.91% Intraday chart for Annovis Bio, Inc. -13.46% -74.22%
Apr. 30 Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating MT
Apr. 29 Sector Update: Health Care Stocks Edge Higher Late Afternoon MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Annovis Bio : Regulation FD Presentation - Form 8-K
PU
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
GL
Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT
Top Midday Decliners
MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
MT
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study
MT
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial
RE
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
GL
Annovis Bio, Inc. Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer?s Disease
CI
Annovis Bio : Material Agreement - Form 8-K
PU
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
GL
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans
CI
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Top Midday Gainers
MT
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
AQ
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
CI
Annovis Bio : Material Event - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. News Annovis Bio, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW